Corbus Pharmaceuticals Holding (CRBP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.48 (+3.03%), Market cap $0.20B, 52-week low–high $6.90 ~ $19.36.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Corbus Pharmaceuticals Holding are updated in real time on BlackAll Trade.
Corbus Pharmaceuticals Holding trades at $7.48 (+3.03%). Real-time quotes and charts are available on BlackAll Trade.
Corbus Pharmaceuticals Holding has a market cap of about $0.20B.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets